SYNERGY has obtained the European Pharmacopoeia Adaptation Certificate
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, SYNERGY announced that the company recently received the revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor issued by the European Directorate for the Quality of Medicines (EDQM). The main reason for this change is the addition of a new production workshop, and the certification scope is: Ticagrelor active pharmaceutical ingredient. The revised certificate will take effect from September 12, 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments